TMS is a noninvasive neuromodulation therapy that uses magnetic pulses to stimulate targeted regions of the brain implicated in mood regulation. While the FDA has approved TMS for treatment-resistant major depressive disorder and obsessive-compulsive disorder, its use in bipolar disorder remains off-label. However, growing clinical evidence suggests TMS may reduce depressive symptoms in people with bipolar disorder, particularly when traditional treatments such as mood stabilizers and psychotherapy are insufficient. Some pilot and open-label trials have reported response rates up to 70–80% and remission rates around 40% for bipolar depression, with a relatively low risk of triggering mania when carefully managed.